Catalogue preview · final packaging and presentation may vary if stockedFive choices across your ballotUse votes only for compounds you would consider ordering
One vote per compoundEach candidate can be selected once on this browser
Flexible interest signalRemove or reassign a vote whenever you like
FOXO4
FOXO4 in peptide catalogues usually means FOXO4-DRI, a D-retro-inverso peptide designed to disrupt the FOXO4–p53 interaction in senescent cells. The shorthand is incomplete, so the exact sequence and stereochemistry must be verified.
Loading your saved choices…
FOXO4 is currently being evaluated through customer voting and is not available to order. Final product specifications and batch documentation will be published only if it joins the catalogue.
This page records catalogue interest only. If FOXO4 is selected for supply, Puffin will publish the confirmed format, batch documentation, and laboratory preparation information on the product listing.
Storage and handling requirements depend on the final supplied format. Confirmed instructions will be provided with the batch details if this candidate is added to the catalogue.
Understanding Foxo4
Explore the science, research focus, and key information behind this compound.
What is Foxo4?+
FOXO4-related peptides are selected for targeted work on transcription-factor signalling and cellular senescence.
What Researchers Study+
Researchers examine FOXO4 pathway activity, Cellular-senescence models, and Stress-response signalling.
How Foxo4 Works+
Senescent cells can use FOXO4 to retain p53 in the nucleus and resist apoptosis. FOXO4-DRI was designed to disturb that interaction, allowing p53 relocation and selective death in some senescent-cell models. In plain language, the peptide tries to remove a survival signal from selected aged cells.
Research at a Glance+
Senescent-cell targeting improved selected mouse outcomes. A 2017 study reported that FOXO4-DRI promoted apoptosis in senescent cells and improved several measures in aged and chemotherapy-exposed mice. It was not a human longevity trial. Read the primary Cell paper. “FOXO4” is a protein name, not a complete product description. The research peptide’s retro-inverso design and D-amino-acid stereochemistry are central to stability and function. An unspecified FOXO4 label cannot support the same evidence claim. Senolytic activity is not proven human rejuvenation. Clearing cells in selected laboratory models can reveal biology while leaving delivery, tissue effects, immune consequences, dosing, and long-term safety unanswered.
If this candidate is added to the catalogue, it would be offered for controlled laboratory research only. It is not for human consumption and is not represented as a medicine, treatment, supplement, or substitute for an approved product.